Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 result for capmatinib

  1. Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) (TA884)

    NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    3 May 2023

    Sections for TA884